54.227.97.219
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Conference Roundup

Six-year natural history comparison shows maralixibat improves event-free survival in ALGS

Maralixibat (MRX) may improve event-free survival (EFS) in patients with Alagille syndrome (ALGS) compared to patients with natural history, according to data from a 6-year real-world evidence (RWE) analysis presented at the American Association for the Study of Liver Diseases annual congress, The Liver Meeting. A total of 84 patients...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-